Sarsys Past Earnings Performance
Past criteria checks 0/6
Sarsys's earnings have been declining at an average annual rate of -41.2%, while the Aerospace & Defense industry saw earnings growing at 15.7% annually. Revenues have been declining at an average rate of 18% per year.
Key information
-41.2%
Earnings growth rate
-40.7%
EPS growth rate
| Aerospace & Defense Industry Growth | 14.9% |
| Revenue growth rate | -18.0% |
| Return on equity | -103.6% |
| Net Margin | -12.6% |
| Last Earnings Update | 31 Dec 2023 |
Revenue & Expenses BreakdownBeta
How Sarsys makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 44 | -6 | 26 | 0 |
| 30 Sep 23 | 42 | -5 | 25 | 0 |
| 30 Jun 23 | 37 | -8 | 26 | 0 |
| 31 Mar 23 | 36 | -7 | 28 | 0 |
| 31 Dec 22 | 37 | -10 | 30 | 0 |
| 30 Sep 22 | 35 | -10 | 32 | 0 |
| 30 Jun 22 | 35 | -9 | 32 | 0 |
| 31 Mar 22 | 36 | -11 | 31 | 0 |
| 31 Dec 21 | 35 | -13 | 31 | 0 |
| 30 Sep 21 | 47 | -10 | 31 | 0 |
| 30 Jun 21 | 60 | -2 | 31 | 0 |
| 31 Mar 21 | 60 | -2 | 32 | 0 |
| 31 Dec 20 | 68 | 0 | 34 | 0 |
| 30 Sep 20 | 75 | 0 | 36 | 0 |
| 30 Jun 20 | 74 | -4 | 37 | 0 |
| 31 Mar 20 | 87 | 0 | 38 | 0 |
| 31 Dec 19 | 92 | 4 | 38 | 0 |
| 30 Sep 19 | 82 | 4 | 36 | 0 |
| 30 Jun 19 | 78 | 4 | 37 | 0 |
| 31 Mar 19 | 67 | 0 | 34 | 0 |
| 31 Dec 18 | 59 | -5 | 31 | 0 |
| 30 Sep 18 | 51 | -5 | 26 | 0 |
| 30 Jun 18 | 43 | -5 | 21 | 0 |
| 31 Mar 18 | 38 | -2 | 17 | 0 |
| 31 Dec 17 | 33 | 1 | 13 | 0 |
| 31 Dec 16 | 17 | 1 | 7 | 0 |
| 31 Dec 15 | 14 | 0 | 6 | 0 |
| 31 Dec 14 | 18 | 1 | 5 | 0 |
| 31 Dec 13 | 18 | 0 | 6 | 0 |
Quality Earnings: SARS is currently unprofitable.
Growing Profit Margin: SARS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SARS is unprofitable, and losses have increased over the past 5 years at a rate of 41.2% per year.
Accelerating Growth: Unable to compare SARS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SARS is unprofitable, making it difficult to compare its past year earnings growth to the Aerospace & Defense industry (36.8%).
Return on Equity
High ROE: SARS has a negative Return on Equity (-103.56%), as it is currently unprofitable.